Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135:1357–1377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438

Article  PubMed  PubMed Central  Google Scholar 

Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34:520–528. https://doi.org/10.1093/eurheartj/ehs123

CAS  Article  PubMed  Google Scholar 

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140:16–26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169

CAS  Article  PubMed  Google Scholar 

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68:161–172. https://doi.org/10.1016/j.jacc.2016.03.596

CAS  Article  PubMed  PubMed Central  Google Scholar 

Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442–1448. https://doi.org/10.1136/heartjnl-2012-302353

Article  PubMed  Google Scholar 

Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076–1084. https://doi.org/10.1016/j.jacc.2005.05.073

Article  PubMed  Google Scholar 

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404–2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612

CAS  Article  PubMed  Google Scholar 

González-López E, Gallego-Delgado M, Guzzo-Merello G, Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585–2594. https://doi.org/10.1093/eurheartj/ehv338

CAS  Article  PubMed  Google Scholar 

Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113–122. https://doi.org/10.1016/j.jchf.2013.11.004

Article  PubMed  PubMed Central  Google Scholar 

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim J-S, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46–58. https://doi.org/10.1056/NEJMoa2028631

CAS  Article  PubMed  Google Scholar 

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689

CAS  Article  PubMed  Google Scholar 

Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493–502. https://doi.org/10.1056/NEJMoa2107454

CAS  Article  PubMed  Google Scholar 

Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (2019) Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407

Article  PubMed  PubMed Central  Google Scholar 

González-López E, Gagliardi C, Dominguez F, Quarta CC, Haro-Del MoralMilandri FJA, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38:1895–1904. https://doi.org/10.1093/eurheartj/ehx043

CAS  Article  PubMed  Google Scholar 

Busse R, Blümel M, Knieps F, Bärnighausen T (2017) Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet 390:882–897. https://doi.org/10.1016/S0140-6736(17)31280-1

Article  Google Scholar 

Westin O, Butt JH, Gustafsson F, Schou M, Salomo M, Køber L, Maurer M, Fosbøl EL (2021) Two decades of cardiac amyloidosis: a Danish nationwide study. JACC CardioOncol 3:522–533. https://doi.org/10.1016/j.jaccao.2021.05.004

Article  PubMed  PubMed Central  Google Scholar 

Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M (2021) Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol 3:537–546. https://doi.org/10.1016/j.jaccao.2021.08.009

Article  PubMed  PubMed Central  Google Scholar 

Devesa A, Camblor Blasco A, Pello Lázaro AM, Askari E, Lapeña G, Gómez Talavera S, Taibo Urquía M, Rodríguez Olleros C, Tuñón J, Ibáñez B, Aceña Á (2021) Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail 8:2856–2865. https://doi.org/10.1002/ehf2.13360

Article  PubMed  PubMed Central  Google Scholar 

AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6:1267–1274. https://doi.org/10.1001/jamacardio.2021.3070

Article  PubMed  Google Scholar 

Palladini G, Milani P (2021) The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease. Leuk Lymphoma 62:1793–1794. https://doi.org/10.1080/10428194.2021.1913152

Article  PubMed  Google Scholar 

Okuda Y, Yamada T, Ueda M, Ando Y (2018) First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Intern Med 57:3351–3355. https://doi.org/10.2169/internalmedicine.1099-18

CAS  Article  PubMed  PubMed Central  Google Scholar 

Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G (2020) ATTRv amyloidosis Italian registry: clinical and epidemiological data. Amyloid 27:259–265. https://doi.org/10.1080/13506129.2020.1794807

CAS  Article  PubMed  Google Scholar 

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126:612–615. https://doi.org/10.1182/blood-2015-01-620302

CAS  Article  PubMed  Google Scholar 

Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, Hanna M (2016) Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67:2941–2948. https://doi.org/10.1016/j.jacc.2016.03.593

CAS  Article  PubMed  Google Scholar 

Bézard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Gendre T, Audard V, El Karoui K, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Planté-Bordeneuve V, Oghina S, Damy T (2021) Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail 23:264–274. https://doi.org/10.1002/ejhf.2028

CAS  Article  PubMed  Google Scholar 

Grobe T, Szecsnyi J Arztreport 2021. https://www.bifg.de/publikationen/reporte/arztreport-2021. Accessed 2 Jan 2022

Figueroa JF, Papanicolas I, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR, Deeny S, Estupiñán-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Shatrov K, van de Galien O, van Gool K, Wodchis W, Jha AK (2021) International comparison of health spending and utilization among people with complex multimorbidity. Health Serv Res 56(Suppl 3):1317–1334. https://doi.org/10.1111/1475-6773.13708

Article  PubMed  PubMed Central  Google Scholar 

Dörr M, Riemer U, Christ M, Bauersachs J, Bosch R, Laufs U, Neumann A, Scherer M, Störk S, Wachter R (2021) Hospitalizations for heart failure: Still major differences between East and West Germany 30 years after reunification. ESC Heart Fail 8:2546–2555. https://doi.org/10.1002/ehf2.13407

Article  PubMed  PubMed Central  Google Scholar 

Hoffmann F, Icks A (2012) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 74:291–297. https://doi.org/10.1055/s-0031-1275711

CAS  Article  PubMed  Google Scholar 

Sun AZ, Shu Y-H, Harrison TN, Hever A, Jacobsen SJ, O’Shaughnessy MM, Sim JJ (2020) Identifying patients with rare disease using electronic health record data: the Kaiser Permanente Southern California Membranous Nephropathy Cohort. Perm J. https://doi.org/10.7812/TPP/19.126

Article  PubMed 

留言 (0)

沒有登入
gif